Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1998 2
2001 1
2002 2
2003 2
2005 3
2006 4
2007 3
2008 1
2009 4
2010 2
2011 3
2012 3
2013 1
2014 2
2015 2
2017 1
2018 3
2019 2
2021 1
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross-sectional study based on the FranceCoag registry.
Nguyen NAT, Auquier P, Beltran Anzola A, Harroche A, Castet S, Huguenin Y, Meunier S, Repesse Y, D'Oiron R, Rauch A, Desprez D, Spiegel A, Chamouni P, Schneider P, Baumstarck K, Boucekine M, Tabele C, Viprey M, Leroy T, Roques MA, Sannie T, Giraud N, Chambost H, Resseguier N; TRANSHEMO Study group. Nguyen NAT, et al. Haemophilia. 2023 Sep;29(5):1202-1218. doi: 10.1111/hae.14841. Epub 2023 Aug 12. Haemophilia. 2023. PMID: 37572328
Ectopic pregnancy in Conakry, Guinea.
Thonneau P, Hijazi Y, Goyaux N, Calvez T, Keita N. Thonneau P, et al. Among authors: calvez t. Bull World Health Organ. 2002;80(5):365-70. Bull World Health Organ. 2002. PMID: 12077611 Free PMC article.
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins PW, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E, van Hardeveld EM, van den Berg M, Keller-Stanislawski B. Volkers P, et al. Among authors: calvez t. Haemophilia. 2019 May;25(3):398-407. doi: 10.1111/hae.13747. Epub 2019 May 7. Haemophilia. 2019. PMID: 31066174 Review.
Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A.
Saultier P, Guillaume Y, Demiguel V, Berger C, Borel-Derlon A, Claeyssens S, Harroche A, Oudot C, Rafowicz A, Trossaert M, Wibaut B, Vinciguerra C, Boucekine M, Baumstarck K, Meunier S, Calvez T, Chambost H; FranceCoag PUPs / CoMETH Prophylaxis Study Group; Hemophilia Treatment Centers of Paris-Necker. Saultier P, et al. Among authors: calvez t. J Pediatr. 2021 Jul;234:212-219.e3. doi: 10.1016/j.jpeds.2021.02.071. Epub 2021 Mar 4. J Pediatr. 2021. PMID: 33676933 Clinical Trial.
Proteolytic antibodies activate factor IX in patients with acquired hemophilia.
Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repessé Y, Ollivier V, Friboulet A, Borel-Derlon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S. Wootla B, et al. Among authors: calvez t. Blood. 2011 Feb 17;117(7):2257-64. doi: 10.1182/blood-2010-07-296103. Epub 2010 Dec 3. Blood. 2011. PMID: 21131590 Free article. Clinical Trial.
37 results